Technical Analysis for CNTB - Connect Biopharma Holdings Limited

Grade Last Price % Change Price Change
D 1.44 -5.26% -0.08
CNTB closed down 5.26 percent on Monday, July 1, 2024, on 34 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -5.26%
50 DMA Resistance Bearish -5.26%
Slingshot Bearish Bearish Swing Setup -5.26%
Bullish Engulfing Bullish -5.26%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 6 hours ago
Gap Up Closed about 9 hours ago
Down 5% about 9 hours ago
Down 3% about 9 hours ago
Down 2 % about 9 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Connect Biopharma Holdings Limited Description

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunology Immune System Immunotherapy Inflammation Asthma Atopic Dermatitis Chronic Rhinosinusitis Human Physiology Skin Inflammation Animal Physiology Interleukins Nasal Polyps

Is CNTB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.84
52 Week Low 0.5347
Average Volume 82,205
200-Day Moving Average 1.31
50-Day Moving Average 1.58
20-Day Moving Average 1.59
10-Day Moving Average 1.42
Average True Range 0.21
RSI (14) 45.05
ADX 16.7
+DI 22.67
-DI 15.87
Chandelier Exit (Long, 3 ATRs) 1.45
Chandelier Exit (Short, 3 ATRs) 1.87
Upper Bollinger Bands 2.00
Lower Bollinger Band 1.18
Percent B (%b) 0.32
BandWidth 51.98
MACD Line -0.08
MACD Signal Line -0.05
MACD Histogram -0.0236
Fundamentals Value
Market Cap 79.3 Million
Num Shares 55.1 Million
EPS -1.56
Price-to-Earnings (P/E) Ratio -0.92
Price-to-Sales 0.00
Price-to-Book 0.47
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.77
Resistance 3 (R3) 1.80 1.71 1.72
Resistance 2 (R2) 1.71 1.63 1.70 1.70
Resistance 1 (R1) 1.58 1.58 1.54 1.55 1.68
Pivot Point 1.49 1.49 1.47 1.48 1.49
Support 1 (S1) 1.36 1.41 1.31 1.33 1.20
Support 2 (S2) 1.27 1.36 1.26 1.18
Support 3 (S3) 1.13 1.27 1.16
Support 4 (S4) 1.11